Back to search
Parkinson's Disease Psychosis
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Parkinson's Disease Psychosis trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Parkinson's Disease Psychosis trials you may qualify forThe goal of this study is to use ultra-high-resolution (UHR) PET imaging to better understand how the brain and spinal cord change in healthy aging and in neuro…
This clinical trial will test whether AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) can improve symptoms of psychosis in Parkinson's disease.…
The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when…
Patients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking probl…
This is an in vivo positron emission tomography (PET) study of regional cerebral dopamine and blood flow in normal volunteers, persons with Parkinson s disease…
The purpose of this study is to evaluate the safety and efficacy of 34 mg pimavanserin compared to placebo in patients with Parkinson's disease psychosis (PDP).
To assess the effect of pimavanserin on the activities of daily living in subjects with Parkinson's Disease Psychosis